NEW YORK (GenomeWeb) – BGI and Clearbridge BioMedics said today that they have signed a partnership agreement, under which they will solely distribute and market Clearbridge's ClearCell FX1 solution and related liquid biopsy products in China.

BGI said that it also hopes to use its genomics expertise and capabilities to extend Clearbridge's ClearCell FX1 circulating tumor cell system into new clinical research applications, as well as develop specific clinical products using the platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.